In today’s briefing:
- Hanwha Aero: Base Case Is the Raise Goes Through
- China Healthcare Weekly (Apr.20)- Giant Biogene Announced a HK$2.3bn Placement, China’s VBP Outlook
Hanwha Aero: Base Case Is the Raise Goes Through
- FSS has quietly greenlit Hanwha Aero’s raise — current pushback is just optics, with defense being too strategic for regulators to risk sending the wrong signal.
- Hanwha Aero’s second updated filing should check the FSS box, and Hanwha Energy swapping cash for equity gives regulators cover to bless the deal without catching heat.
- Base case is the raise goes through — trade the window between the amended filing and effective date, and shorts can still join the deal if they cover in time.
China Healthcare Weekly (Apr.20)- Giant Biogene Announced a HK$2.3bn Placement, China’s VBP Outlook
- With policy optimization and market adjustment, the VBP will pay more attention to the balance between quality, supply, and price. So, we think malignant price competition would be avoided.
- By 2025, the VBP of biosimilar drugs will gradually cover the major categories such as monoclonal antibody, growth hormone and blood products, with an average price reduction of 30%-50%
- Giant Biogene announced a HK$2.294 billion placement with Placing Price of HK$66.65/Share. Investment logic/fundamentals will change after Class III medical device is approved.Based on 2025-2027 forecast, growth will remain strong.
Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
Unlock all research summaries